Text Size
31 studies found for:    myeloma and carfilzomib | Open Studies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Not yet recruiting Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Conditions: Relapse Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Recruiting Filgrastim in Treating Patients With Bortezomib- or Carfilzomib-Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: G-CSF and Bortezomib or Carfilzomib
3 Recruiting A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Dexamethasone
4 Recruiting Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
5 Recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim
6 Recruiting Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Phase I Dose level -1; Carfilzomib and panobinstat;   Drug: Phase I Dose Level 1, Carfilzomib and Panobinostat;   Drug: Phase I Dose Level 2; carfilzomib and panobinostat;   Drug: Phase 1 Dose level 3; carfilzomib and panobinostat;   Drug: Phase I dose level 4; carfilzomib and panobinostat;   Drug: Phase II Dose Level TBD; carfilzomib and panobinostat
7 Recruiting Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
8 Recruiting A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
9 Not yet recruiting Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
10 Recruiting Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Condition: Multiple Myeloma
Interventions: Drug: Group A: Carfilzomib & Non-IMiD Regimen;   Drug: Group B: Carfilzomib & IMiD containing regimen.
11 Recruiting Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: Panobinostat
12 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
13 Not yet recruiting Study of the Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Patients With Progressive Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib and Dexamethasone
14 Not yet recruiting Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
15 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
16 Recruiting Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
17 Recruiting Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: Dexamethasone;   Drug: Clarithromycin;   Drug: Lenalidomide
18 Recruiting Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: pegylated liposomal doxorubicin (PLD);   Drug: Dexamethasone
19 Recruiting A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
20 Recruiting Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
To Top

Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results
† Indicates status has not been verified in more than two years